December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

9.225 -0.145 (-1.55%)
Streaming Delayed Price Updated: 1:06 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗
Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement. 
Via Stocktwits
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio. 
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it. 
Via Investor's Business Daily
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. 
Via Stocktwits
News headline image
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Day One (DAWN) Q2 Revenue Jumps 313% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss ↗
Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances. 
Via Chartmill
News headline image
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
Via AB Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.